NEOADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN FOLLOWED BY MAINTENANCE THERAPY WITH THE EGFR INHIBITOR ERLOTINIB (TARCEVA) SURGERY FOR NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING DEFINITIVE SURGICAL RESECTION: